Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)
Purpose To determine the efficacy of a definitive radiotherapy protocol using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a low cumulative dose schedule in nonbulky early-stage cervical cancer patients, we conducted a prospective multi-institutional study. Methods and Materials Eligib...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2012, Vol.82 (1), p.e49-e56 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e56 |
|---|---|
| container_issue | 1 |
| container_start_page | e49 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 82 |
| creator | Toita, Takafumi, M.D., Ph.D Kato, Shingo, M.D., Ph.D Niibe, Yuzuru, M.D., Ph.D Ohno, Tatsuya, M.D., Ph.D Kazumoto, Tomoko, M.D., Ph.D Kodaira, Takeshi, M.D., Ph.D Kataoka, Masaaki, M.D., Ph.D Shikama, Naoto, M.D., Ph.D Kenjo, Masahiro, M.D., Ph.D Tokumaru, Sunao, M.D Yamauchi, Chikako, M.D., Ph.D Suzuki, Osamu, M.D., Ph.D Sakurai, Hideyuki, M.D., Ph.D Numasaki, Hodaka, Ph.D Teshima, Teruki, M.D., Ph.D Oguchi, Masahiko, M.D., Ph.D Kagami, Yoshikazu, M.D., Ph.D Nakano, Takashi, M.D., Ph.D Hiraoka, Masahiro, M.D., Ph.D Mitsuhashi, Norio, M.D., Ph.D |
| description | Purpose To determine the efficacy of a definitive radiotherapy protocol using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a low cumulative dose schedule in nonbulky early-stage cervical cancer patients, we conducted a prospective multi-institutional study. Methods and Materials Eligible patients had squamous cell carcinoma of the intact uterine cervix, Federation of Gynecologic Oncology and Obstetrics (FIGO) stages Ib1, IIa, and IIb, tumor size |
| doi_str_mv | 10.1016/j.ijrobp.2011.01.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22055948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301611001532</els_id><sourcerecordid>1356925168</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4382-e5962fb53d78b49f4b9cef718d9da93d77153cb6e449e7d871eee67c0b2d059e3</originalsourceid><addsrcrecordid>eNqFkt1u0zAYhiMEYmVwBwhZ4qQ7SGc7zp-EJo0Otk6DTi0TnFmO82V1l9rFdirlKrklHLJxwAmSpVjW8_3kfd8oekvwjGCSnW5namtNtZ9RTMgMh0Pps2hCiryMkzT98Tya4CTDcRLgo-iVc1uMA5mzl9ERJSzHeckm0a9ba9wepFcHQF-61qt4oZ1XvvPKaNGite_qHpkGXUCjtPrDrUStjN-AFfsefVd-g67U_Sa-MA7ilfCAFtpbIcVBeWF79DHcN_0TrzS6FV6B9m6s_Wp01bUPPZp-YLHcnYSR4j70QELXaLFAdx6s0oDmYA9KhpXmQkuwaHp9vlpeYobJ6fVquQ63mJ68jl40onXw5vF7HN19_vRtfhXfLC8X8_ObWLKkoDGkZUabKk3qvKhY2bCqlNDkpKjLWpThNSdpIqsMGCshr4ucAECWS1zRGqclJMfR-7GvCWJxJ5UHuZFG6yAlpxSnacmKQE1Ham_Nzw6c5zvlJLSt0GA6x0mSZiVNSTagbERlMMRZaPjeql2QjxPMB8P5lo-G88FwjsOhNJS9e5zQVTuo_xY9ORyAsxGAoMZBgR2WhSBgreywa23U_yb820C2IQjBiAfowW1NZ0NOwr9wRznm6yF0Q-YICXFLE5r8Brn50tw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356925168</pqid></control><display><type>article</type><title>Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Toita, Takafumi, M.D., Ph.D ; Kato, Shingo, M.D., Ph.D ; Niibe, Yuzuru, M.D., Ph.D ; Ohno, Tatsuya, M.D., Ph.D ; Kazumoto, Tomoko, M.D., Ph.D ; Kodaira, Takeshi, M.D., Ph.D ; Kataoka, Masaaki, M.D., Ph.D ; Shikama, Naoto, M.D., Ph.D ; Kenjo, Masahiro, M.D., Ph.D ; Tokumaru, Sunao, M.D ; Yamauchi, Chikako, M.D., Ph.D ; Suzuki, Osamu, M.D., Ph.D ; Sakurai, Hideyuki, M.D., Ph.D ; Numasaki, Hodaka, Ph.D ; Teshima, Teruki, M.D., Ph.D ; Oguchi, Masahiko, M.D., Ph.D ; Kagami, Yoshikazu, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Hiraoka, Masahiro, M.D., Ph.D ; Mitsuhashi, Norio, M.D., Ph.D</creator><creatorcontrib>Toita, Takafumi, M.D., Ph.D ; Kato, Shingo, M.D., Ph.D ; Niibe, Yuzuru, M.D., Ph.D ; Ohno, Tatsuya, M.D., Ph.D ; Kazumoto, Tomoko, M.D., Ph.D ; Kodaira, Takeshi, M.D., Ph.D ; Kataoka, Masaaki, M.D., Ph.D ; Shikama, Naoto, M.D., Ph.D ; Kenjo, Masahiro, M.D., Ph.D ; Tokumaru, Sunao, M.D ; Yamauchi, Chikako, M.D., Ph.D ; Suzuki, Osamu, M.D., Ph.D ; Sakurai, Hideyuki, M.D., Ph.D ; Numasaki, Hodaka, Ph.D ; Teshima, Teruki, M.D., Ph.D ; Oguchi, Masahiko, M.D., Ph.D ; Kagami, Yoshikazu, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Hiraoka, Masahiro, M.D., Ph.D ; Mitsuhashi, Norio, M.D., Ph.D</creatorcontrib><description>Purpose To determine the efficacy of a definitive radiotherapy protocol using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a low cumulative dose schedule in nonbulky early-stage cervical cancer patients, we conducted a prospective multi-institutional study. Methods and Materials Eligible patients had squamous cell carcinoma of the intact uterine cervix, Federation of Gynecologic Oncology and Obstetrics (FIGO) stages Ib1, IIa, and IIb, tumor size <40 mm in diameter (assessed by T2-weighted magnetic resonance imaging), and no pelvic/para-aortic lymphadenopathy. The treatment protocol consisted of whole-pelvis external beam radiotherapy (EBRT) of 20 Gy/10 fractions, pelvic EBRT with midline block of 30 Gy/15 fractions, and HDR-ICBT of 24 Gy/4 fractions (at point A). The cumulative biologically effective dose (BED) was 62 Gy10 (α/β = 10) at point A. The primary endpoint was the 2-year pelvic disease progression-free (PDPF) rate. All patients received a radiotherapy quality assurance review. Results Between September 2004 and July 2007, 60 eligible patients were enrolled. Thirty-six patients were assessed with FIGO stage Ib1; 12 patients with stage IIa; and 12 patients with stage IIb. Median tumor diameter was 28 mm (range, 6–39 mm). Median overall treatment time was 43 days. Median follow-up was 49 months (range, 7–72 months). Seven patients developed recurrences: 3 patients had pelvic recurrences (2 central, 1 nodal), and 4 patients had distant metastases. The 2-year PDPF was 96% (95% confidence interval [CI], 92%–100%). The 2-year disease-free and overall survival rates were 90% (95% CI, 82%–98%) and 95% (95% CI, 89%–100%), respectively. The 2-year late complication rates (according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer of Grade ≥1) were 18% (95% CI, 8%–28%) for large intestine/rectum, 4% (95% CI, 0%–8%) for small intestine, and 0% for bladder. No Grade ≥3 cases were observed for genitourinary/gastrointestinal late complications. Conclusions These results suggest that definitive radiotherapy using HDR-ICBT with a low cumulative dose schedule (BED, 62 Gy10 at point A) can provide excellent local control without severe toxicity in nonbulky (<4-cm) early-stage cervical cancer.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2011.01.022</identifier><identifier>PMID: 21470794</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; BEAMS ; BLADDER ; BRACHYTHERAPY ; Brachytherapy - methods ; Carcinoma of the cervix ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - secondary ; CARCINOMAS ; Disease-Free Survival ; DOSE RATES ; Dose response ; Dose-Response Relationship, Radiation ; Female ; GYNECOLOGY ; Hematology, Oncology and Palliative Medicine ; High-dose-rate ; Humans ; Intracavitary brachytherapy ; METASTASES ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; NMR IMAGING ; PATIENTS ; PELVIS ; Prospective Studies ; QUALITY ASSURANCE ; RADIATION DOSES ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiotherapy ; RECTUM ; Rectum - radiation effects ; Relative Biological Effectiveness ; SCHEDULES ; SMALL INTESTINE ; TOXICITY ; Tumor Burden ; Urinary Bladder - radiation effects ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - radiotherapy ; Young Adult</subject><ispartof>International journal of radiation oncology, biology, physics, 2012, Vol.82 (1), p.e49-e56</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4382-e5962fb53d78b49f4b9cef718d9da93d77153cb6e449e7d871eee67c0b2d059e3</citedby><cites>FETCH-LOGICAL-c4382-e5962fb53d78b49f4b9cef718d9da93d77153cb6e449e7d871eee67c0b2d059e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301611001532$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21470794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22055948$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Toita, Takafumi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kato, Shingo, M.D., Ph.D</creatorcontrib><creatorcontrib>Niibe, Yuzuru, M.D., Ph.D</creatorcontrib><creatorcontrib>Ohno, Tatsuya, M.D., Ph.D</creatorcontrib><creatorcontrib>Kazumoto, Tomoko, M.D., Ph.D</creatorcontrib><creatorcontrib>Kodaira, Takeshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kataoka, Masaaki, M.D., Ph.D</creatorcontrib><creatorcontrib>Shikama, Naoto, M.D., Ph.D</creatorcontrib><creatorcontrib>Kenjo, Masahiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Tokumaru, Sunao, M.D</creatorcontrib><creatorcontrib>Yamauchi, Chikako, M.D., Ph.D</creatorcontrib><creatorcontrib>Suzuki, Osamu, M.D., Ph.D</creatorcontrib><creatorcontrib>Sakurai, Hideyuki, M.D., Ph.D</creatorcontrib><creatorcontrib>Numasaki, Hodaka, Ph.D</creatorcontrib><creatorcontrib>Teshima, Teruki, M.D., Ph.D</creatorcontrib><creatorcontrib>Oguchi, Masahiko, M.D., Ph.D</creatorcontrib><creatorcontrib>Kagami, Yoshikazu, M.D., Ph.D</creatorcontrib><creatorcontrib>Nakano, Takashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Hiraoka, Masahiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Mitsuhashi, Norio, M.D., Ph.D</creatorcontrib><title>Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To determine the efficacy of a definitive radiotherapy protocol using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a low cumulative dose schedule in nonbulky early-stage cervical cancer patients, we conducted a prospective multi-institutional study. Methods and Materials Eligible patients had squamous cell carcinoma of the intact uterine cervix, Federation of Gynecologic Oncology and Obstetrics (FIGO) stages Ib1, IIa, and IIb, tumor size <40 mm in diameter (assessed by T2-weighted magnetic resonance imaging), and no pelvic/para-aortic lymphadenopathy. The treatment protocol consisted of whole-pelvis external beam radiotherapy (EBRT) of 20 Gy/10 fractions, pelvic EBRT with midline block of 30 Gy/15 fractions, and HDR-ICBT of 24 Gy/4 fractions (at point A). The cumulative biologically effective dose (BED) was 62 Gy10 (α/β = 10) at point A. The primary endpoint was the 2-year pelvic disease progression-free (PDPF) rate. All patients received a radiotherapy quality assurance review. Results Between September 2004 and July 2007, 60 eligible patients were enrolled. Thirty-six patients were assessed with FIGO stage Ib1; 12 patients with stage IIa; and 12 patients with stage IIb. Median tumor diameter was 28 mm (range, 6–39 mm). Median overall treatment time was 43 days. Median follow-up was 49 months (range, 7–72 months). Seven patients developed recurrences: 3 patients had pelvic recurrences (2 central, 1 nodal), and 4 patients had distant metastases. The 2-year PDPF was 96% (95% confidence interval [CI], 92%–100%). The 2-year disease-free and overall survival rates were 90% (95% CI, 82%–98%) and 95% (95% CI, 89%–100%), respectively. The 2-year late complication rates (according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer of Grade ≥1) were 18% (95% CI, 8%–28%) for large intestine/rectum, 4% (95% CI, 0%–8%) for small intestine, and 0% for bladder. No Grade ≥3 cases were observed for genitourinary/gastrointestinal late complications. Conclusions These results suggest that definitive radiotherapy using HDR-ICBT with a low cumulative dose schedule (BED, 62 Gy10 at point A) can provide excellent local control without severe toxicity in nonbulky (<4-cm) early-stage cervical cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>BEAMS</subject><subject>BLADDER</subject><subject>BRACHYTHERAPY</subject><subject>Brachytherapy - methods</subject><subject>Carcinoma of the cervix</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>CARCINOMAS</subject><subject>Disease-Free Survival</subject><subject>DOSE RATES</subject><subject>Dose response</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>GYNECOLOGY</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>High-dose-rate</subject><subject>Humans</subject><subject>Intracavitary brachytherapy</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>NMR IMAGING</subject><subject>PATIENTS</subject><subject>PELVIS</subject><subject>Prospective Studies</subject><subject>QUALITY ASSURANCE</subject><subject>RADIATION DOSES</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiotherapy</subject><subject>RECTUM</subject><subject>Rectum - radiation effects</subject><subject>Relative Biological Effectiveness</subject><subject>SCHEDULES</subject><subject>SMALL INTESTINE</subject><subject>TOXICITY</subject><subject>Tumor Burden</subject><subject>Urinary Bladder - radiation effects</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - radiotherapy</subject><subject>Young Adult</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt1u0zAYhiMEYmVwBwhZ4qQ7SGc7zp-EJo0Otk6DTi0TnFmO82V1l9rFdirlKrklHLJxwAmSpVjW8_3kfd8oekvwjGCSnW5namtNtZ9RTMgMh0Pps2hCiryMkzT98Tya4CTDcRLgo-iVc1uMA5mzl9ERJSzHeckm0a9ba9wepFcHQF-61qt4oZ1XvvPKaNGite_qHpkGXUCjtPrDrUStjN-AFfsefVd-g67U_Sa-MA7ilfCAFtpbIcVBeWF79DHcN_0TrzS6FV6B9m6s_Wp01bUPPZp-YLHcnYSR4j70QELXaLFAdx6s0oDmYA9KhpXmQkuwaHp9vlpeYobJ6fVquQ63mJ68jl40onXw5vF7HN19_vRtfhXfLC8X8_ObWLKkoDGkZUabKk3qvKhY2bCqlNDkpKjLWpThNSdpIqsMGCshr4ucAECWS1zRGqclJMfR-7GvCWJxJ5UHuZFG6yAlpxSnacmKQE1Ham_Nzw6c5zvlJLSt0GA6x0mSZiVNSTagbERlMMRZaPjeql2QjxPMB8P5lo-G88FwjsOhNJS9e5zQVTuo_xY9ORyAsxGAoMZBgR2WhSBgreywa23U_yb820C2IQjBiAfowW1NZ0NOwr9wRznm6yF0Q-YICXFLE5r8Brn50tw</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Toita, Takafumi, M.D., Ph.D</creator><creator>Kato, Shingo, M.D., Ph.D</creator><creator>Niibe, Yuzuru, M.D., Ph.D</creator><creator>Ohno, Tatsuya, M.D., Ph.D</creator><creator>Kazumoto, Tomoko, M.D., Ph.D</creator><creator>Kodaira, Takeshi, M.D., Ph.D</creator><creator>Kataoka, Masaaki, M.D., Ph.D</creator><creator>Shikama, Naoto, M.D., Ph.D</creator><creator>Kenjo, Masahiro, M.D., Ph.D</creator><creator>Tokumaru, Sunao, M.D</creator><creator>Yamauchi, Chikako, M.D., Ph.D</creator><creator>Suzuki, Osamu, M.D., Ph.D</creator><creator>Sakurai, Hideyuki, M.D., Ph.D</creator><creator>Numasaki, Hodaka, Ph.D</creator><creator>Teshima, Teruki, M.D., Ph.D</creator><creator>Oguchi, Masahiko, M.D., Ph.D</creator><creator>Kagami, Yoshikazu, M.D., Ph.D</creator><creator>Nakano, Takashi, M.D., Ph.D</creator><creator>Hiraoka, Masahiro, M.D., Ph.D</creator><creator>Mitsuhashi, Norio, M.D., Ph.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>2012</creationdate><title>Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)</title><author>Toita, Takafumi, M.D., Ph.D ; Kato, Shingo, M.D., Ph.D ; Niibe, Yuzuru, M.D., Ph.D ; Ohno, Tatsuya, M.D., Ph.D ; Kazumoto, Tomoko, M.D., Ph.D ; Kodaira, Takeshi, M.D., Ph.D ; Kataoka, Masaaki, M.D., Ph.D ; Shikama, Naoto, M.D., Ph.D ; Kenjo, Masahiro, M.D., Ph.D ; Tokumaru, Sunao, M.D ; Yamauchi, Chikako, M.D., Ph.D ; Suzuki, Osamu, M.D., Ph.D ; Sakurai, Hideyuki, M.D., Ph.D ; Numasaki, Hodaka, Ph.D ; Teshima, Teruki, M.D., Ph.D ; Oguchi, Masahiko, M.D., Ph.D ; Kagami, Yoshikazu, M.D., Ph.D ; Nakano, Takashi, M.D., Ph.D ; Hiraoka, Masahiro, M.D., Ph.D ; Mitsuhashi, Norio, M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4382-e5962fb53d78b49f4b9cef718d9da93d77153cb6e449e7d871eee67c0b2d059e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>BEAMS</topic><topic>BLADDER</topic><topic>BRACHYTHERAPY</topic><topic>Brachytherapy - methods</topic><topic>Carcinoma of the cervix</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>CARCINOMAS</topic><topic>Disease-Free Survival</topic><topic>DOSE RATES</topic><topic>Dose response</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>GYNECOLOGY</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>High-dose-rate</topic><topic>Humans</topic><topic>Intracavitary brachytherapy</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>NMR IMAGING</topic><topic>PATIENTS</topic><topic>PELVIS</topic><topic>Prospective Studies</topic><topic>QUALITY ASSURANCE</topic><topic>RADIATION DOSES</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiotherapy</topic><topic>RECTUM</topic><topic>Rectum - radiation effects</topic><topic>Relative Biological Effectiveness</topic><topic>SCHEDULES</topic><topic>SMALL INTESTINE</topic><topic>TOXICITY</topic><topic>Tumor Burden</topic><topic>Urinary Bladder - radiation effects</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - radiotherapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toita, Takafumi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kato, Shingo, M.D., Ph.D</creatorcontrib><creatorcontrib>Niibe, Yuzuru, M.D., Ph.D</creatorcontrib><creatorcontrib>Ohno, Tatsuya, M.D., Ph.D</creatorcontrib><creatorcontrib>Kazumoto, Tomoko, M.D., Ph.D</creatorcontrib><creatorcontrib>Kodaira, Takeshi, M.D., Ph.D</creatorcontrib><creatorcontrib>Kataoka, Masaaki, M.D., Ph.D</creatorcontrib><creatorcontrib>Shikama, Naoto, M.D., Ph.D</creatorcontrib><creatorcontrib>Kenjo, Masahiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Tokumaru, Sunao, M.D</creatorcontrib><creatorcontrib>Yamauchi, Chikako, M.D., Ph.D</creatorcontrib><creatorcontrib>Suzuki, Osamu, M.D., Ph.D</creatorcontrib><creatorcontrib>Sakurai, Hideyuki, M.D., Ph.D</creatorcontrib><creatorcontrib>Numasaki, Hodaka, Ph.D</creatorcontrib><creatorcontrib>Teshima, Teruki, M.D., Ph.D</creatorcontrib><creatorcontrib>Oguchi, Masahiko, M.D., Ph.D</creatorcontrib><creatorcontrib>Kagami, Yoshikazu, M.D., Ph.D</creatorcontrib><creatorcontrib>Nakano, Takashi, M.D., Ph.D</creatorcontrib><creatorcontrib>Hiraoka, Masahiro, M.D., Ph.D</creatorcontrib><creatorcontrib>Mitsuhashi, Norio, M.D., Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toita, Takafumi, M.D., Ph.D</au><au>Kato, Shingo, M.D., Ph.D</au><au>Niibe, Yuzuru, M.D., Ph.D</au><au>Ohno, Tatsuya, M.D., Ph.D</au><au>Kazumoto, Tomoko, M.D., Ph.D</au><au>Kodaira, Takeshi, M.D., Ph.D</au><au>Kataoka, Masaaki, M.D., Ph.D</au><au>Shikama, Naoto, M.D., Ph.D</au><au>Kenjo, Masahiro, M.D., Ph.D</au><au>Tokumaru, Sunao, M.D</au><au>Yamauchi, Chikako, M.D., Ph.D</au><au>Suzuki, Osamu, M.D., Ph.D</au><au>Sakurai, Hideyuki, M.D., Ph.D</au><au>Numasaki, Hodaka, Ph.D</au><au>Teshima, Teruki, M.D., Ph.D</au><au>Oguchi, Masahiko, M.D., Ph.D</au><au>Kagami, Yoshikazu, M.D., Ph.D</au><au>Nakano, Takashi, M.D., Ph.D</au><au>Hiraoka, Masahiro, M.D., Ph.D</au><au>Mitsuhashi, Norio, M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2012</date><risdate>2012</risdate><volume>82</volume><issue>1</issue><spage>e49</spage><epage>e56</epage><pages>e49-e56</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose To determine the efficacy of a definitive radiotherapy protocol using high-dose-rate intracavitary brachytherapy (HDR-ICBT) with a low cumulative dose schedule in nonbulky early-stage cervical cancer patients, we conducted a prospective multi-institutional study. Methods and Materials Eligible patients had squamous cell carcinoma of the intact uterine cervix, Federation of Gynecologic Oncology and Obstetrics (FIGO) stages Ib1, IIa, and IIb, tumor size <40 mm in diameter (assessed by T2-weighted magnetic resonance imaging), and no pelvic/para-aortic lymphadenopathy. The treatment protocol consisted of whole-pelvis external beam radiotherapy (EBRT) of 20 Gy/10 fractions, pelvic EBRT with midline block of 30 Gy/15 fractions, and HDR-ICBT of 24 Gy/4 fractions (at point A). The cumulative biologically effective dose (BED) was 62 Gy10 (α/β = 10) at point A. The primary endpoint was the 2-year pelvic disease progression-free (PDPF) rate. All patients received a radiotherapy quality assurance review. Results Between September 2004 and July 2007, 60 eligible patients were enrolled. Thirty-six patients were assessed with FIGO stage Ib1; 12 patients with stage IIa; and 12 patients with stage IIb. Median tumor diameter was 28 mm (range, 6–39 mm). Median overall treatment time was 43 days. Median follow-up was 49 months (range, 7–72 months). Seven patients developed recurrences: 3 patients had pelvic recurrences (2 central, 1 nodal), and 4 patients had distant metastases. The 2-year PDPF was 96% (95% confidence interval [CI], 92%–100%). The 2-year disease-free and overall survival rates were 90% (95% CI, 82%–98%) and 95% (95% CI, 89%–100%), respectively. The 2-year late complication rates (according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer of Grade ≥1) were 18% (95% CI, 8%–28%) for large intestine/rectum, 4% (95% CI, 0%–8%) for small intestine, and 0% for bladder. No Grade ≥3 cases were observed for genitourinary/gastrointestinal late complications. Conclusions These results suggest that definitive radiotherapy using HDR-ICBT with a low cumulative dose schedule (BED, 62 Gy10 at point A) can provide excellent local control without severe toxicity in nonbulky (<4-cm) early-stage cervical cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21470794</pmid><doi>10.1016/j.ijrobp.2011.01.022</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2012, Vol.82 (1), p.e49-e56 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22055948 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged BEAMS BLADDER BRACHYTHERAPY Brachytherapy - methods Carcinoma of the cervix Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - secondary CARCINOMAS Disease-Free Survival DOSE RATES Dose response Dose-Response Relationship, Radiation Female GYNECOLOGY Hematology, Oncology and Palliative Medicine High-dose-rate Humans Intracavitary brachytherapy METASTASES Middle Aged Neoplasm Recurrence, Local Neoplasm Staging NMR IMAGING PATIENTS PELVIS Prospective Studies QUALITY ASSURANCE RADIATION DOSES Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy RECTUM Rectum - radiation effects Relative Biological Effectiveness SCHEDULES SMALL INTESTINE TOXICITY Tumor Burden Urinary Bladder - radiation effects Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - radiotherapy Young Adult |
| title | Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20Multi-Institutional%20Study%20of%20Definitive%20Radiotherapy%20With%20High-Dose-Rate%20Intracavitary%20Brachytherapy%20in%20Patients%20With%20Nonbulky%20(%3C4-cm)%20Stage%20I%20and%20II%20Uterine%20Cervical%20Cancer%20(JAROG0401/JROSG04-2)&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Toita,%20Takafumi,%20M.D.,%20Ph.D&rft.date=2012&rft.volume=82&rft.issue=1&rft.spage=e49&rft.epage=e56&rft.pages=e49-e56&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2011.01.022&rft_dat=%3Cproquest_osti_%3E1356925168%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356925168&rft_id=info:pmid/21470794&rft_els_id=S0360301611001532&rfr_iscdi=true |